Switch theme
Sign up to access all valuation multiples
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region.
2013
745
LTM Revenue $273M
LTM EBITDA $39.8M
$323M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Knight Therapeutics has a last 12-month revenue (LTM) of $273M and a last 12-month EBITDA of $39.8M.
In the most recent fiscal year, Knight Therapeutics achieved revenue of $268M and an EBITDA of $46.5M.
Knight Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Knight Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $273M | XXX | $268M | XXX | XXX | XXX |
| Gross Profit | $126M | XXX | $126M | XXX | XXX | XXX |
| Gross Margin | 46% | XXX | 47% | XXX | XXX | XXX |
| EBITDA | $39.8M | XXX | $46.5M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 17% | XXX | XXX | XXX |
| EBIT | $14.2M | XXX | $5.3M | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 2% | XXX | XXX | XXX |
| Net Profit | $4.0M | XXX | $3.1M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | 1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Knight Therapeutics's stock price is CAD 6 (or $4).
Knight Therapeutics has current market cap of CAD 574M (or $414M), and EV of CAD 447M (or $323M).
See Knight Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $323M | $414M | XXX | XXX | XXX | XXX | $0.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Knight Therapeutics has market cap of $414M and EV of $323M.
Knight Therapeutics's trades at 1.2x EV/Revenue multiple, and 6.9x EV/EBITDA.
Equity research analysts estimate Knight Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Knight Therapeutics has a P/E ratio of 104.2x.
See valuation multiples for Knight Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $414M | XXX | $414M | XXX | XXX | XXX |
| EV (current) | $323M | XXX | $323M | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | 8.1x | XXX | 6.9x | XXX | XXX | XXX |
| EV/EBIT | 22.6x | XXX | 60.4x | XXX | XXX | XXX |
| EV/Gross Profit | 2.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 104.2x | XXX | 132.5x | XXX | XXX | XXX |
| EV/FCF | 11.2x | XXX | 93.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKnight Therapeutics's last 12 month revenue growth is 9%
Knight Therapeutics's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Knight Therapeutics's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Knight Therapeutics's rule of X is 37% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Knight Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | -1% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | 21% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 45% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Knight Therapeutics acquired XXX companies to date.
Last acquisition by Knight Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Knight Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Knight Therapeutics founded? | Knight Therapeutics was founded in 2013. |
| Where is Knight Therapeutics headquartered? | Knight Therapeutics is headquartered in Canada. |
| How many employees does Knight Therapeutics have? | As of today, Knight Therapeutics has 745 employees. |
| Who is the CEO of Knight Therapeutics? | Knight Therapeutics's CEO is Ms. Samira Sakhia. |
| Is Knight Therapeutics publicy listed? | Yes, Knight Therapeutics is a public company listed on TSE. |
| What is the stock symbol of Knight Therapeutics? | Knight Therapeutics trades under GUD ticker. |
| When did Knight Therapeutics go public? | Knight Therapeutics went public in 2014. |
| Who are competitors of Knight Therapeutics? | Similar companies to Knight Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Knight Therapeutics? | Knight Therapeutics's current market cap is $414M |
| What is the current revenue of Knight Therapeutics? | Knight Therapeutics's last 12 months revenue is $273M. |
| What is the current revenue growth of Knight Therapeutics? | Knight Therapeutics revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Knight Therapeutics? | Current revenue multiple of Knight Therapeutics is 1.2x. |
| Is Knight Therapeutics profitable? | Yes, Knight Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Knight Therapeutics? | Knight Therapeutics's last 12 months EBITDA is $39.8M. |
| What is Knight Therapeutics's EBITDA margin? | Knight Therapeutics's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Knight Therapeutics? | Current EBITDA multiple of Knight Therapeutics is 8.1x. |
| What is the current FCF of Knight Therapeutics? | Knight Therapeutics's last 12 months FCF is $28.7M. |
| What is Knight Therapeutics's FCF margin? | Knight Therapeutics's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Knight Therapeutics? | Current FCF multiple of Knight Therapeutics is 11.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
